Sangamo Therapeutics, Inc. Common Stock (SGMO) is a publicly traded Healthcare sector company. As of May 20, 2026, SGMO trades at $0.18 with a market cap of $55.93M and a P/E ratio of -0.40. SGMO moved +31.04% today. Year to date, SGMO is -59.51%; over the trailing twelve months it is -75.61%. Its 52-week range spans $0.12 to $3.18. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces SGMO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Sangamo Therapeutics Delisting May 5 After Missing Bid Price, Moves to OTCQB: Sangamo Therapeutics will be delisted from Nasdaq on May 5, 2026 after failing to meet the minimum bid price requirement and will begin trading on the OTCQB Venture Market under SGMO. The company plans to appeal the decision and pursue capital-raising and strategic partnerships to support operations.
| Metric | Value |
|---|---|
| Price | $0.18 |
| Market Cap | $55.93M |
| P/E Ratio | -0.40 |
| EPS | $-0.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.18 |
| 52-Week Low | $0.12 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $39.55M |
| Net Income | $-122.93M |
| Gross Margin | 0.00% |
2 analysts cover SGMO: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.